

HEADER

Letter head, contact details.

Dear Doctor,

Patient
details.....

Summary of
attendance.....

Important drug information- please read.

Infliximab and Adalimumab are potent immunosuppressant drugs which can increase the risk of infection whilst masking symptoms. Prompt action should be taken in the event of infection and patients should be advised **NOT to administer adalimumab or attend for infliximab**, and to contact the Gastroenterology department prior to restarting treatment.

No live vaccines should be given to patients on infliximab or adalimumab.

Infliximab and Adalimumab are prescribed and supplied by the Gastroenterology department. Hence you will **not** be asked for prescriptions for these medications.

GPs are encouraged to add infliximab or adalimumab as a hospital issued drug in order to pick up potential interactions. There is a useful reminder on how to do this [here](#):